Serum fibroblast growth factor 19 and endogenous islet beta cell function in type 2 diabetic patients

Abstract

Background Fibroblast growth factor 19 (FGF19) takes part in maintaining the balance of glycolipids and may be involved in regulating the secretory activity of islet beta cells in patients with type 2 diabetes. This study aimed to evaluate the relationship between the levels of serum FGF19 and endogenous islet beta cell function in type 2 diabetic patients. Methods Samples were obtained from 271 subjects: 85 drug-naïve type 2 diabetes participants exclusively on lifestyle intervention (N-DM group), 122 type 2 diabetes subjects previously used medications (DM group) and 64 normal controls (NC group). Serum FGF19 concentrations were measured by ELISA. The insulin sensitivity (MI), insulin secretion (AUCins/AUCglu) and insulin secretion-sensitivity index-2 (ISSI-2) were also measured in the N-DM and DM. Results Serum FGF19 levels decreased, in order, from the NC group [median (interquartile range), 245.03 (126.23–317.43) pg/mL] to the N-DM group [170.05 (89.01–244.70) pg/mL] and, finally, to the DM group [142.25 (55.55–187.58) pg/mL] (p for trend < 0.05). Among subjects in the DM group, there was a positive trend in the serum FGF19 concentration; plasma insulin levels at 60 min, 120 min (INS60, INS120, respectively); and area under the insulin curve (AUCins) at two points (r = 0.214, p = 0.025; r = 0.189, p = 0.048; r = 0.188, p = 0.049). However, the differences were no longer observed among the N-DM subjects. Simultaneously, the ISSI-2 was closely related to the serum FGF19 levels (r = 0.297, p = 0.002) among DM subjects. Furthermore, after adjusting for age, sex, duration, therapy and other clinical factors via multiple logistic regression analysis, ISSI-2 was a key independent factor in the levels of FGF19 (β = 0.281, t = 2.557, p = 0.013). Conclusions The serum FGF19 level has a close relation with endogenous beta cell function among DM subjects, as assessed by the ISSI-2. As ISSI-2 is higher in N-DM group, FGF19 may be a main protector in dysfunction of beta cell.

Association of serum fibroblast growth factor 19 levels with arteriosclerosis parameters assessed by arterial stiffness and atherogenic index of plasma in patients with type 2 diabetes

“…The main function of FGF19 is to regulate the synthesis of bile acid (BA) by acting on cholesterol 7α-hydroxylase (CYP7A1) [13,14]. As shown in our previous study, FGF19 participates in maintaining the balance of glucose and may protect against the dysfunction of β-cells [15]. The serum FGF19 levels in CAD subjects are lower than those in subjects without CAD and are correlated with the presence and severity of CAD [16].…”

“…Hepatic steatosis on ultrasound was used to establish the diagnosis of non-alcoholic fatty liver disease (NAFLD). The calculation of the homeostatic model assessment for insulin sensitivity (IS HOMA-cp ) [18], Body mass index (BMI), AIP and NAFLD fibrosis score (NFS) was as follows: IS HOMA-cp = 22.5/ (glucose × C-peptide in fasting status); BMI = the weight/the height squared; AIP = TG/HDL-c; NFS = − 1.675 + 0.037 × age (years) + 0.094 × BMI (kg/m 2 ) + 1.13 × IFG/diabetes (yes = 1, no = 0) + 0.99 × AST/ALT ratio-0.013 × platelet (× 10 9 /l) − 0.66 × albumin (g/dl) [15].…”

Inverse Association of Serum Fibroblast Growth Factor 19 and Atherogenic Index of Plasma in Type 2 Diabetic Patients

“…The main function of FGF19 is to regulate the synthesis of bile acid (BA) by acting on cholesterol 7α-hydroxylase (CYP7A1) [8,9]. As shown in our previous study, FGF19 participates in maintaining the balance of glucose and may protect against the dysfunction of β-cells [10]. The serum FGF19 levels in CAD subjects are lower than those in subjects without CAD and are correlated with the presence and severity of CAD [11].…”

Association of serum fibroblast growth factor 19 levels with arteriosclerosis parameters assessed by arterial stiffness and atherogenic index of plasma in patients with type 2 diabetes

“…Hepatic steatosis on ultrasound was used to establish the diagnosis of NAFLD. The calculation of the homeostatic model assessment for insulin sensitivity (IS HOMA-cp ) [18], BMI, AIP and NAFLD fibrosis score (NFS) was as follows: IS HOMA-cp = 22.5/(glucose × C-peptide in fasting status); BMI = the weight/the height squared; AIP = TG/HDL-c; NFS = -1.675 + 0.037 × age (years) + 0.094 × BMI (kg/m 2 ) + 1.13 × IFG/diabetes (yes = 1, no = 0) + 0.99 × AST/ALT ratio-0.013 × platelet (×10 9 /l)-0.66 × albumin (g/dl) [15].…”

“…The main function of FGF19 is to regulate the synthesis of bile acid (BA) by acting on cholesterol 7α-hydroxylase (CYP7A1) [13,14]. As shown in our previous study, FGF19 participates in maintaining the balance of glucose and may protect against the dysfunction of β-cells [15]. The serum FGF19 levels in CAD subjects are lower than those in subjects without CAD and are correlated with the presence and severity of CAD [16].…”